News about Global Pharma

Sandoz Begins Construction Of USD 440 Million Biosimilars Production Facility In Slovenia

Sandoz is constructing a new facility in Slovenia to strengthen its European biosimilar hub and expand its global market presence.

Global Pharma | 10/07/2025 | By Dineshwori |  480

Centrient Pharmaceuticals Appoints New Site Director for Delft Facility

Centrient Pharmaceuticals has announced the appointment of Pierre-Yves Dalla-Libera as the new Site Director for its Delft facility, effective September 1, 2025.

Global Pharma | 10/07/2025 | By Dineshwori |  641

Merck to Acquire Verona Pharma for USD 10 Billion to Expand Cardio-Pulmonary Portfolio

Merck, through a subsidiary, will acquire Verona Pharma for USD 107 per American Depository Share (ADS), each of which represents eight shares of Verona Pharma, for a total transaction value of approximately USD 10 billion.

Global Pharma | 10/07/2025 | By Dineshwori |  449

Global API Market Expected to Reach USD 422.8 Billion by 2034

The global Active Pharmaceutical Ingredients (API) market is projected to grow at a compound annual growth rate (CAGR) of 6.7 percent to an estimated USD 422.8 billion by 2034, according to a report.

Global Pharma | 09/07/2025 | By Dineshwori |  209

Lupin Signs USD 50 million Deal with Zentiva to Commercialise Biosimilar Certolizumab Pegol Globally

Zentiva will be responsible for marketing and distribution of Lupin’s biosimilar Certolizumab Pegol outside the USA and Canada—primarily across Europe and the CIS (Commonwealth of Independent States) region.

Global Pharma | 09/07/2025 | By Dineshwori |  350

Nectar to Sell API, Formulations and Menthol Units to Ceph for INR 1,290 Cr

Nectar Lifesciences Ltd. is selling its core business division for INR 1,270 crore and its menthol business for INR 20 crore to Ceph Lifesciences.

Global Pharma | 09/07/2025 | By Dineshwori |  647

GSK Completes Acquisition of Efimosfermin from Boston Pharmaceuticals for USD 2 Billion

GSK has completed its acquisition of efimosfermin alfa, a Phase III-ready investigational therapy for serious liver diseases, from Boston Pharmaceuticals in a deal worth up to USD 2 billion.

Global Pharma | 09/07/2025 | By Mrinmoy Dey |  322

Mold-Tek Projects INR 30-35 Crore from Pharma Segment in FY26

Hyderabad-based Mold-Tek Packaging is witnessing strong growth in its pharmaceutical packaging segment, with ambitious targets of INR 30–35 crore in revenue for FY26 and INR 50–60 crore by FY27.

Global Pharma | 08/07/2025 | By Manvi |  192

Alembic Pharma Appoints Former Syngene VP G Krishnan as New CFO

G Krishnan has taken over as the new Chief Financial Officer (CFO) of Alembic Pharmaceuticals, succeeding R. K. Baheti.

Global Pharma | 08/07/2025 | By Manvi |  736

ACIP Dismissals Spark Regulatory Uncertainty as ADCs Surge in Biopharma Innovation

The action has sent shockwaves through the public health and vaccine development communities, raising concerns about regulatory continuity and future vaccine rollouts, according to GlobalData.

Global Pharma | 08/07/2025 | By Darshana |  246